KellBenx Licenses Interleukin Biomarkers from Cedars-Sinai

The Long Island, NY-based company will use the three biomarkers to develop blood-based tests to predict premature births.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.

Related Stories